Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

Pharmaceuticals 2020 October 2 [Link] Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Diana Cao, Ingrid J G Burvenich, Angela Rigopoulos, Edward B Reilly, Thomas John, Andrew M Scott Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a…

Read More

Cisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report

Medicine 2020 May 29 [Link] Hiroaki Ikushima, Toshio Sakatani, Sayaka Ohara, Hideyuki Takeshima, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui Abstract Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be…

Read More

18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.

Interactive Cardiovascular and Thoracic Surgery 2020 January 31 [Link] Lococo F, Rena O, Torricelli F, Filice A, Rapicetta C, Boldorini R, Paci M, Versari A Abstract Although 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan has been generally validated in the staging of malignant pleural mesothelioma (MPM), its diagnostic and prognostic performances are not clearly established.…

Read More

Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.

BioMed Research International 2019 December 20 [Link] Pehlivan B, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E Abstract OBJECTIVE: To compare volumetric arc therapy (VMAT) and helical tomotherapy (HT) plans in terms of dosimetric parameters in positron emission tomography- (PET-) computerized tomography- (CT-) based radiation therapy planning in unresectable malignant pleural…

Read More

Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Annals of Gastroenterology 2018 Nov-Dec [Link] Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely,…

Read More

Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Clinical Lung Cancer 2018 September 3 [Link] Fodor A1, Broggi S2, Incerti E3, Dell’Oca I4, Fiorino C2, Samanes Gajate AM3, Pasetti M4, Cattaneo MG2, Passoni P4, Gianolli L3, Calandrino R2, Picchio M, Di Mu Abstract INTRODUCTION: The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without…

Read More

MR Imaging of Pleural Neoplasms

Topics in Magnetic Resonance Imaging [2018 April] [Link] Carter BW, Betancourt SL, Shroff GS, Lichtenberger JP 3rd Abstract The pleura may be affected by primary tumors or metastatic spread of intrathoracic or extrathoracic neoplasms. Primary pleural neoplasms represent ∼10% of all pleural tumors, and malignant lesions are more common than benign lesions. The most common…

Read More

18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center

The British Journal of Radiology 2018 March [Epub ahead of print] [Link] H St. AE et.al. Abstract OBJECTIVE: To compare the N and M staging accuracy of positron emission tomography (PET) versus CT, as per the American Joint Committee on Cancer (AJCC) 8th edition in patients with malignant pleural mesothelioma (MPM) being considered for multimodality…

Read More